查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
第一線醫療團隊如何有效應對罕見疾病領域：Expert Q&A
市場調查報告書
商品編碼
1773146

第一線醫療團隊如何有效應對罕見疾病領域：Expert Q&A

Expert Q&A: How Field Medical Teams Effectively Traverse Rare Disease Terrain
出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2個工作天內

價格
簡介目錄

第一線醫療團隊的任務是彌合前沿科學與臨床實踐之間的差距，尤其是在複雜的罕見疾病領域。

這些疾病帶來了獨特的挑戰，包括資料有限、患者群體規模小且地理分佈分散，以及未滿足的醫療需求巨大。對第一線醫療專業人員來說，這意味著要應對科學上的不確定性，與專家建立深厚的關係，並擔任倡議者。

FirstWord訪問了Kyowa Kirin北部群聚醫療主管 Gillian Logan，探討了一線醫療團隊如何應對罕見疾病領域的挑戰。

關鍵問題：

  • 第一線醫療團隊在與罕見疾病領域的醫療專業人員（HCP）合作時面臨的最緊迫挑戰是什麼？
  • 協和麒麟如何客製化其醫療事務策略以滿足罕見疾病族群的獨特需求？
  • RWE 在塑造罕見疾病第一線醫療活動中扮演什麼角色？
  • 協和麒麟的第一線醫療團隊如何平衡科學交流需求與罕見疾病照護的情感和倡導面向？
  • 哪些工具和技術對支援罕見疾病第一線醫療團隊最有效？
  • 如何確保不同地區和罕見疾病適應症之間科學交流的一致性和品質？
  • 協和麒麟的第一線醫療團隊如何與病人倡導團體合作並直接與病人合作？
  • 如何將病患的聲音融入第一線醫療策略和訓練中？
  • 與一般疾病領域的專業人員相比，罕見疾病第一線醫療專業人員需要哪些能力和訓練？
  • 預見哪些未來創新和趨勢將塑造罕見疾病第一線醫療保健？

研究方法

檔案報告是基於獨立而簡潔的分析，這些分析源自於專有的產業研究以及對產業意見領袖的深入訪談。報告深入分析了製藥企業高管需要了解的關鍵趨勢和市場發展，以應對即將到來的機會和挑戰。每份報告的重點都基於二手文獻綜述和已確定的知識差距。基於這些初步研究，制定了基於證據、專家指導的討論指南，以確保研究能夠解答最重要的問題。此外，制定了嚴格的篩選標準，以確保受訪者擁有就該主題發言所需的經驗、知識和資格。

報告有何獨特之處？

FirstWord Reports 是值得信賴的行業領導者，致力於製藥業，為生物製藥專業人士和決策者提供詳細且可操作的見解。深厚的行業知識使能夠提供相關且有價值的見解，有助於的客戶掌握新興趨勢並有效解決複雜挑戰。報告以廣泛的研究成果以及來自頂尖專家和關鍵意見領袖（KOL）的獨立客觀見解為後盾，提供所需的準確性和可靠性。透過獨家訪談和資料，加上持續的市場監測，可全面了解市場動態。報告涵蓋 40 多個活躍的疾病領域，匯集了包括關鍵意見領袖（KOL）洞察和定量醫生調查在內的醫生情報，以及行業專家對醫療事務、數位健康、銷售與營銷、市場准入及其他領域問題的看法，助做出更明智的資料驅動決策，在快速變化的行業中保持競爭力。

簡介目錄

Field medical teams bridge the gap between cutting-edge science and clinical practice, especially in the complex area of rare diseases.

These conditions present unique challenges, such as limited data, small and geographically dispersed patient populations, and a high unmet medical need. For field medical professionals, this means navigating scientific uncertainty, building deep relationships with specialists, and serving as advocates.

FirstWord spoke with Gillian Logan, head of medical, northern cluster at Kyowa Kirin, to discuss how field medical teams tackle the challenges within the rare disease space.

Key Questions Answered:

  • What are the most pressing challenges field medical teams face when engaging with HCPs in the rare disease space?
  • How does Kyowa Kirin tailor its medical affairs strategy to address the unique needs of rare disease communities?
  • What role does RWE play in shaping field medical activities for rare diseases?
  • How do field medical teams at Kyowa Kirin balance the need for scientific exchange with the emotional and advocacy aspects of rare disease care?
  • What tools or technologies have proven most effective in supporting field medical teams in rare disease settings?
  • How do you ensure consistency and quality in scientific communication across different regions and rare disease indications?
  • Can you share examples of how Kyowa Kirin's field medical teams collaborate with patient advocacy groups or directly with patients?
  • How do you incorporate the patient voice into field medical strategies and training?
  • What specific competencies or training are essential for field medical professionals working in rare diseases compared with more common conditions?
  • What innovations or trends do you foresee shaping the future of field medical affairs in rare diseases?

Methodology:

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.